33 Herein we report the identification and characterisation of two linear antimicrobial peptides 34 (AMPs), HG2 and HG4, with activity against a wide range of multidrug resistant (MDR) 35 bacteria, especially methicillin resistant Staphylococcus aureus (MRSA) strains, a highly 36 problematic group of Gram-positive bacteria in the hospital and community environment. To 37 identify the novel AMPs presented here, we employed the classifier model design, a feature 38 extraction method using molecular descriptors for amino acids for the analysis, visualization, 39 and interpretation of AMP activities from a rumen metagenomic dataset. This allowed for the in 40 silico discrimination of active and inactive peptides in order to define a small number of 41 promising novel lead AMP test candidates for chemical synthesis and experimental evaluation. In 42 vitro data suggest that the chosen AMPs are fast acting, show strong biofilm inhibition and 43 dispersal activity and are efficacious in an in vivo model of MRSA USA300 infection, whilst 44 showing little toxicity to human erythrocytes and human primary cell lines ex vivo.
Introduction
144 Six most promising AMP sequences (termed Hess-Gene 1-6 (HG1-HG6) (SI Table S2 ) were 145 identified from the 829 sequences we utilized in silico approaches (Materials and Methods) 146 sequences. The corresponding nucleotide sequence and additional information for the 147 identified genes can be found in supporting information S3.
148 Two of these six promising candidates, HG2 (MKKLLLILFCLALALAGCKKAP) and HG4 149 (VLGLALIVGGALLIKKKQAKS) containing 22 and 21 AA residues respectively, were 150 selected for subsequent characterisation. Sequence homology analysis using NCBI's BLASTP 151 36 against the non-redundant (nr) protein sequences suggests that HG2 is most similar to 152 hypothetical or uncharacterised proteins with unknown functions from Treponema 153 maltophilum ATCC 51939, Pedobacter soli and Bacteroides sp., while HG4 is most similar to 154 Na + /H + antiporter NhaC family protein from Fibrobacter sp. UWR2, and a hypothetical protein 155 from Bifidobacterium adolescentis (Table 1) . Similarly, homology analysis of the AMP sequences against the proteins from WGS 160 metagenomic projects (env_nr) suggests that HG2 is most similar to hypothetical proteins from 161 marine metagenomes, while HG4 is most similar to permease of the drug/metabolite transporter 162 (dmt) superfamily identified from a hydrocarbon rich ditch metagenome and hypothetical 163 proteins from marine metagenomes. It is important to note that the AMPs match to only a small 164 part of their homologous sequences. The high e-values and low bit scores and coverage of the 165 homologous sequences to HG2 and HG4 (as the best hits still had relatively high e-values of 166 0.001), as well as the fact that they are automatically curated unreviewed sequences should 167 also be noted, as this indicates the potential novelty of the peptides. Therefore, this study has 168 not only identified HG2 and HG4 sequences from the rumen metagenomic dataset as 169 antimicrobial proteins but may also provide insight into the function of the full proteins 229 The peptides also showed activity against some Gram-negative bacteria strains, specifically 230 some non-resistant A. baumannii strains and P. aeruginosa strains C3719 and LES400 isolated 231 from cystic fibrosis patients ( Table 2 ). 236 Time kill kinetics 237 The bactericidal activity of HG2 and HG4 against logarithmic-phase MRSA USA300 cells was 238 investigated by time kill kinetic studies. Compared with vancomycin and mupirocin, HG2 and 239 HG4 (at 3x MIC concentration) had a rapid bactericidal activity against MRSA USA300 strain 240 ( Fig. 3a) , causing reductions of >3 log 10 CFU/ml and >6 log 10 CFU/ml, respectively, within 241 the first 10 min. HG2 and HG4 induced complete cell death within 5 hours and 10 min of 242 treatment respectively, with no recovery observed after 24 hours of incubation. This rapid and 243 total loss in bacteria cell viability is similar to the killing kinetics that have been reported for 244 many fast acting antimicrobial peptides 15, 53 . As expected, vancomycin and mupirocin at 3x 245 MIC produced ≥2 log 10 CFU/ml reductions attributable to differences in kill kinetics and mode 246 of action 54 . 277 For therapeutic AMP candidates, it is important that bacterial AMP resistance, which may 278 develop due to selective pressure is not based on mutations or acquisition of specific resistance 279 genes, which can then be horizontally transferred between bacteria species as with conventional 280 antibiotics 69, 70 . Here, we assessed the likelihood of resistant mutants and/or resistance arising 281 when MRSA cells are exposed to sub-MIC levels of HG2 and HG4. Continuous exposure of 282 bacteria cells to sub-lethal doses of the AMPs over a period of 20 days did not produce resistant 283 mutants (Fig. 3c ), and MICs remained within 1-2 fold increases compared to mupirocin treated 284 cells, which had a 32-fold MIC increase within the same period. The observed increase in MIC 285 is rather common for many AMP-based molecules as a small change in the MIC after exposure 286 to the AMP is to be expected 71, 72 . Our inability to recover resistant mutants in this experiment 287 suggests that the HG2 and HG4 may have non-specific or multiple cellular targets as has been 288 described previously for peptides 73 .
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Biochemical mode of action studies 291 ATP depletion assay 292 Adenosine triphosphate (ATP) is a high-energy nucleoside triphosphate molecule formed in 293 the cytosol of bacteria and mitochondria of eukaryotes and drives most cellular and metabolic 294 processes in microbial cells [74] [75] [76] . Changes in the concentration of ATP can be used as an 295 indicator of cell viability and competence. We tested the effect of HG2 and HG4 on ATP 296 concentration levels in S. aureus MRSA USA300. As expected, untreated bacteria cells 297 generated increasing amounts of ATP over time, whereas significantly lower concentrations of 298 ATP were observed in HG2 and HG4 treated cells (Fig. 3d ). This decrease in ATP 299 concentrations may be an indication of ATP depletion, limiting cellular energy and thus other 300 related cellular processes (such as substrate transport, homeostasis and anabolism) likely linked 301 to cell membrane disturbance. HG2 and HG4 induced a significant (P = 0.018 and 0.003, 302 respectively) decrease in ATP concentration in S. aureus MRSA USA300 cells, which is 303 similar to what was reported for other cationic AMPs 47, 77 . Hilpert et al 47 demonstrated that 304 many short AMPs had a strong effect on ATP concentration whereas several 26mer α-helical 305 peptides did not.
307 Bacterial membrane permeabilisation assay
308 Since HG2 and HG4 peptides possessed rapid bactericidal effect, we used the propidium iodide 309 (PI) method 15, 78 to determine if these AMPs were able to permeabilise MRSA USA300 310 cytoplasmic membrane similar to what was observed for other rumen derived AMPs 15 . MRSA 311 USA300 cells exposed to increasing concentrations of HG2 or HG4 both showed increase in 312 PI entry/fluorescence over time, demonstrating that they were able to permeate the cytoplasmic 313 membrane and therefore indicating that they may possess pore-forming activity (Fig. 4a, b ).
314 Indeed, significant permeabilisation (p < 0.01) of MRSA USA300 cytoplasmic membrane was 315 observed even at sub-MIC concentrations, e.g. as low as 1 and 16 µg/ml for HG2 and HG4, 316 respectively (MIC values being 16 and 32 µg/ml for HG2 and HG4 respectively). The Effective 317 Concentration 50 (EC50) (defined as the concentration of a drug at which the drug is half-318 maximally effective) of HG2 and HG4 measured after 80 min of incubation were 1.351 (±0.27) 319 and 13.85 (±3.22) µg/ml, while total membrane permeabilisation was observed at 3.9 and 62.4 320 µg/ml, respectively (Fig. 4c ). Membrane permeabilisation kinetics of HG2 and HG4 at their 321 MIC concentration, showed that HG2 was able to permeabilise the membrane faster (80% 322 permeabilisation at 1 min and maximal effect after 5 min) than HG4 (minor permeabilisation 323 at 20 min, maximal effect after 40 min) ( Fig. 4d ). (Table 3) .
353 Cytotoxicity studies on human primary cells and cells lines 354 Cytotoxicity of HG2 and HG4 against different human cell types was evaluated by measuring 355 the IC 50 , which is the concentration of peptide inhibiting 50% of the cell viability. Lung 356 fibroblast (IMR-90) cells were found to be the most sensitive to HG2 and HG4 with IC 50 of 96 357 ± 21 and 294 ± 42 µg/ml for HG2 and HG4. Lung epithelial (BEAS-2B) and liver (HepG2) 358 cells) cells were the least sensitive to HG2 and HG4 with IC 50 of 120 ± 25 and 359 ± 76 µg/ml 359 for HG2 and IC 50 ˃1000 µg/ml for HG4 ( Table 3) . As a whole, cytotoxicity data showed that 360 HG4 was less toxic than HG2 for human cells and that epithelial cell types (BEAS-2B and 361 HEPG2) were the least sensitive, while fibroblast and endothelial cells were more susceptible 362 to the peptides ( Table 3 ). The high hydrophobicity of HG2 may contribute to its higher toxicity 363 to human erythrocytes and cell lines. This is similar to Gramicidins that possess high 364 hydrophobicity ratios and are exclusively used topically due to their haemolytic side-effects 79-365 81 , it is possible that the future application of HG2 might be restricted to topical application to 366 treat superficial infections, unless modified derivatives/analogues of HG2 with improved 367 cytotoxicity become available.
368 Table 3 . Cytotoxicity and haemolytic activities of HG2 and HG4 on human cells. 369 Cytotoxicity is expressed as IC 50 (i.e. the concentration of peptide in µg/ml causing a reduction 370 of 50% of the cell viability). Haemolytic activity is expressed as HC 50 (i.e. the concentration 371 of peptide causing 50% haemolysis). IC 50 and HC 50 are expressed in µg/ml concentrations. 372 Therapeutic Indexes (T.I) corresponding to the fold difference between IC 50 or HC 50 and MIC 373 values (for MRSA USA300) are given in brackets.
Cell type (human)
HG2 (X MIC) HG4 (X MIC) 
BEAS-2B
Peptide-lipid interaction and insertion assay
375 The interaction of HG2 and HG4 with lipid monolayers was measured by the critical pressure 376 of insertion, reflecting the affinity of the peptides for specific lipids. Insertion capacity was 377 first measured using total lipids extracts obtained from MRSA USA300 cells or human 378 erythrocytes (Fig. 6a, b , and SI Table S4 ) and obtained data suggested that HG2 and HG4 had 384 To identify the lipid partner(s) recognized by HG2 and HG4 in bacterial and eukaryotic 385 membranes measurement of the critical pressure of insertion in pure lipids were performed 386 ( Fig. 6c, d and SI Table S4 ). Results indicated that HG2 and HG4 had different affinities and In vivo efficacy studies 416 Galleria mellonella has been used widely as an effective model for testing antimicrobials drugs 417 and their toxicity 82-85 . We investigated the toxicity of HG2 and HG4 against G. mellonella 418 larvae as well as their ability to protect the larvae from a lethal dose of an MRSA USA300 419 infection. The peptides HG2 and HG4 showed no toxic effect in G. mellonella at either 1x MIC 420 or 3x MIC concentrations (Fig. 7a) . As with the control group of larvae, no phenotypic 421 modification such as melanisation and/or motility reduction was observed in larvae injected 422 with HG2 and HG4.
423
424 The MRSA USA300 infective dose (LD 50 ) was determined as being 10 5 CFU/larvae, while the 425 lethal dose (LD) was determined as 2.25x10 6 CFU/larvae (caused melanisation and death of all 426 larvae within 24 h (Fig. 7a ). Larvae infected with MRSA USA300 LD and treated with peptides 427 HG2 and HG4, at 1x MIC concentration had increased survival rate by ~20% (Fig.7b ). In 428 comparison to larvae in the untreated control group, larvae infected with MRSA USA300 LD, 429 followed by treatment with peptides 3x MIC increased survival by 4.6-fold and 4.4-fold for 430 HG2 and HG4 with a survival rate of 78% and 75%, respectively (Fig. 7b ). 
Materials and Methods
474
In silico prediction and identification of AMPs using computational analysis 475 Antimicrobial peptide prediction and similarity analysis was performed on the rumen 476 metagenomic dataset from the study by Hess et al, 19 . The dataset was termed the Library 477 "Cow" dataset and contains 2,547,270 predicted protein sequences 478 ('metagenemark_predictions.faa.gz') which were downloaded from the weblink 479 (http://portal.nersc.gov/project/jgimg/CowRumenRawData/submission/). All other datasets 480 (libraries) used for similarity analysis prediction/identification of novel AMP candidates from 481 the "Cow" dataset and their respective sources are as follows: The Library "AMP1", which 482 contained a list of 2308 known antimicrobial peptides (AMPs) downloaded from APD2 34 504 step and the number of most similar peptide from Library "AMP" were saved as separate 505 features. To select only promising candidates of AMP predictions, only sequences from the 506 Library "Cow" with small AA distances AAD <0.2 or a small AA and AA pair distances AAPD 507 <1.45 were saved. The distances were computed using the 1-norm (Manhattan norm). The 508 thresholds for AAD and AAPD were heuristically chosen to balance the trade-off between too 509 many weak candidates (too high values of AAD and AAPD) vs. the loss of promising 510 candidates (too low values of AAD and AAPD). All sequences that fulfilled the conditions in 511 the preceding step were collected and some interesting hits were used to check similarity in 512 APD2 database (criteria: small values of AAD or AAPD, different neighbours to explore the 513 variety of the candidates found, short peptide length). Finally, descriptors were computed 
550
Anti-biofilm activity 551 The ability of HG2 and HG4 to disrupt established S. aureus biofilms was measured using a 552 96 well format as described by 15 . MRSA USA300 cultures grown overnight in Brain Heart 553 Infusion (BHI) broth was re-suspended to an OD 600nm = 0.02 and grown without shaking at 554 37 o C in 96 well tissue culture plates for another 24 h. The planktonic cells were removed by 555 three PBS (phosphate buffered saline) washes. Thereafter, fresh BHI broth containing peptides 556 HG2 or HG4 at sub-and supra MIC concentrations (0.5X, 1X, 2X and 4X MIC) was added to 557 wells containing adherent cells and incubated without shaking for another 24 h. Planktonic 558 cells were again removed by three PBS washes. Biofilms were fixed with methanol for 20 min, 559 stained with 0.4% (w/v) crystal violet solution for 20 min and re-solubilised with 33% (v/v) 560 acetic acid. The optical density of re-solubilised biofilms was measured at 570 nm in a microplate 561 spectrophotometer. The growth of biofilm per treatment was calculated as a percentage of the 562 untreated cells and anti-biofilm activity was determined for statistically significant treatments.
564
Serial passage/resistance assay 565 In vitro evaluation of the potential for MRSA USA3000 cells to develop resistance to HG2 and 566 HG4 was performed as previously described 95 . Briefly, on Day 1, overnight cultures grown 567 from a single colony of MRSA USA300 strain in MHB at 37 o C with shaking at 225 rpm was 568 subjected to microbroth dilution susceptibility testing performed using a standard doubling-569 dilution series of AMP concentrations as described for MIC determination. Cultures from the 570 highest concentration that supported growth were diluted 1: 1000 in MHB and used to provide 571 the inoculum for the next passage day. This process was continued for 20 days. Any putative 572 mutants recovered were colony purified for three generations on MHA, prior to further 573 characterization.
575
ATP determination assay 576 Adenosine triphosphate (ATP) drives many cellular and metabolic processes and can be used 577 to ascertain the integrity of cells 75, 76 . To determine whether HG2 and HG4 affected ATP levels 578 in S. aureus treated cells, we used the ATP colorimetric/fluorometric assay kit (Sigma Aldrich) 579 which determines ATP concentration by phosphorylating glycerol, resulting in a colorimetric 580 product that shows absorbance at 570nm. Briefly, in a clear 96 well plate, samples and ATP 581 standard provided with the kit were added in a reaction mix containing ATP assay buffer, ATP 582 Probe and Converter and Developer mix. The reaction mix was incubated in the dark at room 583 temperature for 30 min. The absorbance at 570nm was then measured in a microplate 584 spectrophotometer. The background ATP levels obtained from samples and ATP standards 585 were autocorrected by subtracting ATP levels from blank treatments. The amount of ATP in 586 unknown samples were determined from the ATP standard curve and calculated using the 587 formula in the instruction manual. All samples were tested in triplicates.
588
